MCID: SVR005
MIFTS: 53

Severe Pre-Eclampsia

Categories: Cardiovascular diseases, Reproductive diseases, Rare diseases

Aliases & Classifications for Severe Pre-Eclampsia

MalaCards integrated aliases for Severe Pre-Eclampsia:

Name: Severe Pre-Eclampsia 12 55 15 73
Severe Pre-Eclampsia, Antepartum Condition or Complication 73
Severe Pre-Eclampsia, Postpartum Condition or Complication 73
Severe Pre-Eclampsia, with Delivery 12
Antepartum Severe Pre-Eclampsia 12
Postpartum Severe Pre-Eclampsia 12
Severe Preeclampsia 12
Severe Toxemia 73

Classifications:



External Ids:

Disease Ontology 12 DOID:13129
ICD9CM 35 642.50
ICD10 33 O14.1

Summaries for Severe Pre-Eclampsia

Disease Ontology : 12 A pre-eclampsia that has symptom at least one of the following

MalaCards based summary : Severe Pre-Eclampsia, also known as severe pre-eclampsia, antepartum condition or complication, is related to gestational diabetes and antiphospholipid syndrome. An important gene associated with Severe Pre-Eclampsia is HLA-G (Major Histocompatibility Complex, Class I, G), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Methyldopa and Magnesium Sulfate have been mentioned in the context of this disorder. Affiliated tissues include skin, kidney and colon, and related phenotypes are cardiovascular system and homeostasis/metabolism

Related Diseases for Severe Pre-Eclampsia

Diseases in the Eclampsia family:

Pre-Eclampsia Severe Pre-Eclampsia

Diseases related to Severe Pre-Eclampsia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 134)
# Related Disease Score Top Affiliating Genes
1 gestational diabetes 30.0 ADIPOQ LEP RBP4
2 antiphospholipid syndrome 30.0 APOH F5 SERPINC1
3 placental insufficiency 29.8 FGR LEP PGF VEGFA
4 hellp syndrome 29.7 APOH F5 LGALS13 PGF SERPINC1
5 eclampsia 29.1 ALB F5 HLA-G LGALS13 PGF SERPINC1
6 placenta disease 28.2 APOH F5 PGF SERPINC1
7 diabetes mellitus, noninsulin-dependent 28.0 ADIPOQ ALB APLN LEP LEPR RBP4
8 placental abruption 27.6 APOH F5 PGF SERPINC1
9 pre-eclampsia 26.6 ADIPOQ APOH F5 HLA-G LEP LEPR
10 severe nonproliferative diabetic retinopathy 10.8 ALB VEGFA
11 angiokeratoma circumscriptum 10.8 MMP9 VEGFA
12 sick building syndrome 10.6 LEP MMP9 VEGFA
13 acroosteolysis 10.6 ALB VEGFA
14 acquired generalized lipodystrophy 10.6 ADIPOQ LEP
15 lipoblastoma 10.6 LEP LEPR
16 trypanosomiasis 10.6 ALB HLA-G VCAM1
17 obesity-hypoventilation syndrome 10.6 ADIPOQ LEP
18 microvascular complications of diabetes 1 10.6 MMP9 VCAM1 VEGFA
19 adamantinous craniopharyngioma 10.5 MMP9 VEGFA
20 idiopathic recurrent pericarditis 10.5 ADIPOQ LEP
21 brain edema 10.5 ALB MMP9 VEGFA
22 parotitis 10.5 ALB MMP9
23 background diabetic retinopathy 10.5 ALB VEGFA
24 balanitis xerotica obliterans 10.5 APLN VEGFA
25 gastrointestinal system cancer 10.5 ALB MMP9 VEGFA
26 coronary artery aneurysm 10.4 ADIPOQ LEP VCAM1
27 prediabetes syndrome 10.4 ADIPOQ ALB LEP
28 mild pre-eclampsia 10.3 LEP PGF VCAM1
29 fournier gangrene 10.3 ALB SERPINC1
30 glucose metabolism disease 10.3 ADIPOQ ALB LEP
31 lipid metabolism disorder 10.2 ADIPOQ LEP RBP4
32 eating disorder 10.2 ADIPOQ LEP LEPR
33 burns 10.2 ALB SERPINC1
34 overnutrition 10.2 ADIPOQ LEP LEPR
35 morbid obesity 10.2 ADIPOQ LEP LEPR
36 klatskin's tumor 10.1 ALB MMP9
37 aging 10.1
38 retinitis 10.1
39 hyperglycemia 10.1 ADIPOQ ALB LEP
40 arteriosclerosis 10.1 ADIPOQ MMP9 VCAM1
41 amaurosis fugax 10.1 F5 MMP9
42 chronic kidney failure 10.1 ADIPOQ ALB LEP VCAM1
43 neovascular glaucoma 10.1 PGF VEGFA
44 retinal detachment 10.1
45 hydatidiform mole, recurrent, 1 10.1
46 hemolytic anemia 10.1
47 cerebritis 10.1
48 gestational trophoblastic neoplasm 10.1
49 endotheliitis 10.1
50 anorexia nervosa 10.1 ADIPOQ LEP LEPR

Graphical network of the top 20 diseases related to Severe Pre-Eclampsia:



Diseases related to Severe Pre-Eclampsia

Symptoms & Phenotypes for Severe Pre-Eclampsia

MGI Mouse Phenotypes related to Severe Pre-Eclampsia:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.31 RBP4 SERPINC1 VCAM1 MMP9 VEGFA PGF
2 homeostasis/metabolism MP:0005376 10.31 RBP4 SERPINC1 VCAM1 MMP9 VEGFA PGF
3 growth/size/body region MP:0005378 10.16 VEGFA PGF LEPR VCAM1 MMP9 ADIPOQ
4 immune system MP:0005387 10.1 VEGFA PGF SERPINC1 VCAM1 MMP9 LEP
5 embryo MP:0005380 10.08 PGF SERPINC1 VCAM1 VEGFA LEP APLN
6 liver/biliary system MP:0005370 9.97 SERPINC1 VEGFA LEP ALB LEPR F5
7 muscle MP:0005369 9.97 RBP4 MMP9 VEGFA LEP ALB APLN
8 neoplasm MP:0002006 9.8 MMP9 VEGFA PGF LEP ALB LEPR
9 renal/urinary system MP:0005367 9.7 SERPINC1 MMP9 VEGFA ALB LEP LEPR
10 respiratory system MP:0005388 9.5 VEGFA PGF LEPR MMP9 LEP HIF1AN
11 vision/eye MP:0005391 9.23 PGF RBP4 SERPINC1 MMP9 VEGFA LEP

Drugs & Therapeutics for Severe Pre-Eclampsia

Drugs for Severe Pre-Eclampsia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 185)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyldopa Approved Phase 4 555-30-6 38853
2
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 7487-88-9 24083
3
Furosemide Approved, Vet_approved Phase 4 54-31-9 3440
4
Captopril Approved Phase 4 62571-86-2 44093
5
Clonidine Approved Phase 4 4205-90-7 2803
6
Dalteparin Approved Phase 4,Phase 3 9005-49-6
7
Enoxaparin Approved Phase 4,Phase 3,Not Applicable 9005-49-6 772
8
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2 9005-49-6 772 46507594
9
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-78-2 2244
10
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
11
rituximab Approved Phase 4 174722-31-7 10201696
12
Labetalol Approved Phase 4,Phase 2,Phase 3 36894-69-6 3869
13
Acetaminophen Approved Phase 4,Phase 2,Phase 3 103-90-2 1983
14
Ibuprofen Approved Phase 4,Phase 2,Phase 3 15687-27-1 3672
15
Warfarin Approved Phase 4 81-81-2 6691 54678486
16
Nifedipine Approved Phase 4,Phase 2,Phase 3 21829-25-4 4485
17
Benzocaine Approved, Investigational Phase 4,Phase 3 1994-09-7, 94-09-7 2337
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-30-3 6037
19
leucovorin Approved, Nutraceutical Phase 4,Phase 3 58-05-9 143 6006
20 tannic acid Approved, Nutraceutical Phase 4,Phase 3
21 Antihypertensive Agents Phase 4,Phase 2,Phase 3,Not Applicable
22 Anesthetics Phase 4,Phase 2,Phase 3,Not Applicable
23 Calcium, Dietary Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
24 Central Nervous System Depressants Phase 4,Phase 2,Phase 3,Not Applicable
25 Antibodies Phase 4,Phase 2
26 Antibodies, Antiphospholipid Phase 4
27 Anticoagulants Phase 4,Phase 3,Phase 2
28 Immunoglobulins Phase 4,Phase 2
29 Micronutrients Phase 4,Phase 2,Phase 3,Not Applicable
30 Trace Elements Phase 4,Phase 2,Phase 3,Not Applicable
31 Vitamins Phase 4,Phase 2,Phase 3,Not Applicable
32 Antimetabolites Phase 4,Phase 1,Phase 2
33 Analgesics Phase 4,Phase 2,Phase 3,Not Applicable
34 Anti-Arrhythmia Agents Phase 4,Phase 2,Phase 3,Not Applicable
35 Anticonvulsants Phase 4,Phase 2,Phase 3,Not Applicable
36 calcium channel blockers Phase 4,Phase 2,Phase 3,Not Applicable
37 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
38 Pharmaceutical Solutions Phase 4,Phase 3,Not Applicable
39 Tocolytic Agents Phase 4,Phase 2,Phase 3,Not Applicable
40 diuretics Phase 4
41 Natriuretic Agents Phase 4
42 Sodium Potassium Chloride Symporter Inhibitors Phase 4
43 Adrenergic Agents Phase 4,Phase 2,Phase 3
44 Adrenergic Agonists Phase 4,Phase 3,Phase 2
45 Adrenergic alpha-2 Receptor Agonists Phase 4,Phase 2
46 Adrenergic alpha-Agonists Phase 4,Phase 3,Phase 2
47 Angiotensin-Converting Enzyme Inhibitors Phase 4
48 Autonomic Agents Phase 4,Phase 2,Phase 3
49 HIV Protease Inhibitors Phase 4
50 Neurotransmitter Agents Phase 4,Phase 2,Phase 3

Interventional clinical trials:

(show top 50) (show all 115)
# Name Status NCT ID Phase Drugs
1 Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia (Metildopape) Unknown status NCT01361425 Phase 4 methildopa;placebo
2 Effectiveness Study of Short Course of Magnesium Sulfate for Severe Preeclamsia Completed NCT01408979 Phase 4 Magnesium sulfate 12 hours;Magnesium sulfate 24 hours
3 A Trial Comparing Treatment With the Springfusor Infusion Pump to the IV Magnesium Sulfate Regimen Completed NCT02091401 Phase 4 Magnesium Sulfate
4 Diuretics for Postpartum High Blood Pressure in Preeclampsia Completed NCT02163655 Phase 4 FUROSEMIDE;Placebo
5 Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure Completed NCT01761916 Phase 4 CLONIDINE;CAPTOPRIL
6 Low Molecular Weight Heparin in Recurrent Miscarriage With Negative Antiphospholipid Antibodies Completed NCT01608347 Phase 4 LMWH+Folic acid;Folic Acid
7 Topical Brimonidine to Reduce Inflammation After IPL-treatment in Patients With Facial Telangiectasias Completed NCT02761174 Phase 4 Brimonidine
8 Timing of Initiation of LMWH Administration in Pregnant Women With APS Completed NCT02326051 Phase 4 Enoxaparin;Enoxaparin
9 Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers Completed NCT01729468 Phase 4 Aspirin;Placebo
10 A Pilot Study of MabThera (Rituximab) Evaluated by MRI in Patients With Rheumatoid Arthritis. Completed NCT00502853 Phase 4 rituximab [MabThera/Rituxan];Methotrexate
11 Efficacy and Safety of 1 g Vs 2 g Per Hour Intravenous Maintenance Dose of MgSO4 in Women With Severe Pre-eclampsia Recruiting NCT03164304 Phase 4 Magnesium Sulfate
12 Use of Warfarin After the First Trimester in Pregnant Women With APS Recruiting NCT02303171 Phase 4 Enoxaparin;Warfarin
13 Chronic Hypertension and Pregnancy (CHAP) Project Recruiting NCT02299414 Phase 4 Anti-hypertensive therapy
14 Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features Active, not recruiting NCT02911701 Phase 4 Acetaminophen;Ibuprofen
15 Discontinuation of Magnesium Sulfate After Delivery in Women With Severe Preeclampsia. A Randomized Controlled Trial Not yet recruiting NCT03318211 Phase 4 Magnesium Sulfate
16 Different Schemes of Magnesium Sulfate for Preeclampsia Terminated NCT02396030 Phase 4 Magnesium sulfate 50% - 1g/h;Magnesium sulfate 50% - 2g/h
17 Atenativ Effect on Uterine Blood Flow and Preeclampsia Withdrawn NCT02278575 Phase 4 Atenativ
18 Carbetocin vs. Oxytocin for Prevention of Postpartum Bleeding in Patients With Severe Preeclampsia Unknown status NCT01382732 Phase 3 Carbetocin;Oxytocin
19 Prevention of Postpartum Hemorrhage in Patients With Severe Preeclampsia Using Carbetocin Versus Misoprostol Completed NCT02086994 Phase 3 misoprostol;carbetocin
20 Magnesium Sulfate During the Postpartum in Women With Severe Preeclampsia Completed NCT02307201 Phase 2, Phase 3 Magnesium Sulfate
21 Prevention of Maternal and Perinatal Complications by Enoxaparin in Women With Previous Severe Preeclampsia Completed NCT00986765 Phase 3 Lovenox® (enoxaparin);Aspegic ® (Aspirin)
22 Magnesium Sulfate in Pregnancy and Postpartum Completed NCT02317146 Phase 2, Phase 3 Magnesium Sulfate
23 Nonsteroidal Antiinflammatory Drugs in Women With Postpartum Pre-eclampsia Completed NCT01988298 Phase 2, Phase 3 Ibuprofen;Acetaminophen
24 New Magnesium Sulphate Protocol for Pre-eclampsia Completed NCT01846156 Phase 3 MgSO4
25 Antioxidant Supplementation in Pregnant Women Completed NCT01232205 Phase 2, Phase 3
26 A Trial to Evaluate the Ongoing Skin Safety of Testosterone MD-Lotion Formulations Completed NCT00857454 Phase 3 Testosterone MD-Lotion
27 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention Completed NCT01355159 Phase 3 Folic Acid 4 mg;Placebo
28 A Titration Trial to Determine the Effectiveness of Testosterone MD-Lotion (Cutaneous Solution) Formulations Completed NCT00702650 Phase 3 Testosterone MD-Lotion
29 Oral Nifedipine Versus IV Labetalol in Severe Pre Eclampsia Recruiting NCT03325348 Phase 2, Phase 3 Nifedipine 10 mg;Labetalol
30 The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine Recruiting NCT02558023 Phase 3 Urapidil;Nicardipine
31 Use of Sildenafil Citrate in Management of Mild Pre-eclampsia Recruiting NCT03262961 Phase 2, Phase 3 Sildenafil 20 MG;Placebo Oral Tablet
32 Magnesium Sulphate for Preterm Birth (MASP Study) Recruiting NCT01492608 Phase 3 Magnesium sulphate
33 Magnesium Sulfate in Thrombotic Thrombocytopenic Purpura in Intensive Care Not yet recruiting NCT03237819 Phase 3 Sulfate, Magnesium;Placebo - Concentrate
34 Prevention of Preeclampsia With Aspirin in Recipients of Donated Oocytes. Suspended NCT02174328 Phase 3 Acetylsalicylic acid;Placebo
35 Maternal and Neonatal Outcomes of the Use of Vasopressors to Treat Hypotension During Spinal Anesthesia for Cesarean Withdrawn NCT01451060 Phase 3 Metaraminol;Ephedrine
36 Utility of Tocolytic Therapy for Maintenance Tocolysis in the Management of Threatened Preterm Delivery Withdrawn NCT01796522 Phase 3 progesterone 200 mg / day vaginally;nifedipine (60 mg / day orally)
37 Labetalol Versus Magnesium Sulfate (MgSO4) for the Prevention of Eclampsia Trial Withdrawn NCT00293735 Phase 2, Phase 3 labetalol (seizure prevention);MgSO4 (seizure prevention)
38 Rosuvastatin in Order to Induce Preeclampsia Resolution in Severe PET up to 48 Hours Following Delivery Unknown status NCT02314286 Phase 1, Phase 2 Rosuvastatin;Placebo
39 Efficacy Study of Digibind for Treatment of Severe Preeclampsia Completed NCT00158743 Phase 2 Anti-digoxin antibody (FAB fragment)
40 Dexmedetomidine vs. Remifentanil for Pre-eclampsia During Caesarean Delivery Completed NCT01766089 Phase 2 Remifentanil;Dexmedetomidine
41 Safety and Acceptability of a Vaginal Microbicide Completed NCT00111943 Phase 2 1% tenofovir gel
42 Aspirin for the Enhancement of Trophoblastic Invasion in Women With Abnormal Uterine Artery Doppler at 11-14 Weeks of Gestation Completed NCT01616615 Phase 2 Aspirin;placebo
43 Study in Elderly Alzheimer's Patients to Assess Skin Tolerability, Irritation With 3, 7-Day Applications of DTP-System Completed NCT00916383 Phase 2 350 mg Donepezil Transdermal Patch;Placebo Patch
44 A Study for the Transdermal Application of Teriparatide Completed NCT01011556 Phase 2 Subcutaneous Teriparatide;Transdermal Teriparatide
45 Study of the Efficacy and Safety of DigiFab® in Antepartum Subjects With Severe Preeclampsia Recruiting NCT03008616 Phase 2
46 IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy Recruiting NCT03152058 Phase 2 Certolizumab Pegol
47 Should Colon or Non-colon Originated Lesions be Distinguished? Recruiting NCT02939508 Phase 1, Phase 2
48 Usefulness of Extracorporeal Removal of sFLT-1 in Women With Very Early Severe Preeclampsia Terminated NCT02286284 Phase 2
49 Clinical Trial of a COX-2 Inhibitor for the Treatment of Women With Preeclampsia Withdrawn NCT00442676 Phase 2 Celecoxib;Placebo
50 Study of UC-781 Vaginal Microbicide Completed NCT00132444 Phase 1 topical vaginal application of UC-781 gel

Search NIH Clinical Center for Severe Pre-Eclampsia

Genetic Tests for Severe Pre-Eclampsia

Anatomical Context for Severe Pre-Eclampsia

MalaCards organs/tissues related to Severe Pre-Eclampsia:

41
Skin, Kidney, Colon, Placenta, Liver, Lung, Bone

Publications for Severe Pre-Eclampsia

Articles related to Severe Pre-Eclampsia:

(show top 50) (show all 329)
# Title Authors Year
1
Maternal cardiac output response to colloid preload and vasopressor therapy during spinal anaesthesia for caesarean section in patients with severe pre-eclampsia: a randomised, controlled trial. ( 29086911 )
2018
2
Associations of polymorphisms of CYP2D6 and CYP2C9 with early onset severe pre-eclampsia and response to labetalol therapy. ( 29789925 )
2018
3
A case of partial hydatidiform molar pregnancy with a placental diploid-triploid mosaicism associated with a euploid viable foetus complicated with severe pre-eclampsia. ( 29421928 )
2018
4
Baseline check of blood pressure readings of an automated device in severe pre-eclampsia and healthy normotensive pregnancy. ( 29674198 )
2018
5
Molar pregnancy with normal viable fetus presenting with severe pre-eclampsia: a case report. ( 29779493 )
2018
6
Severe pre-eclampsia among pregnant women with sickle cell disease and HIV. ( 29523281 )
2018
7
Treatment using tadalafil for severe pre-eclampsia with fetal growth restriction. ( 28503744 )
2017
8
Validation of fullPIERS model for prediction of adverse outcomes among women with severe pre-eclampsia. ( 28475234 )
2017
9
Assessment of quality of care among in-patients with postpartum haemorrhage and severe pre-eclampsia at st. Francis hospital nsambya: a criteria-based audit. ( 28086822 )
2017
10
Planned caesarean section versus planned vaginal birth for severe pre-eclampsia. ( 29058762 )
2017
11
Prediction of severe pre-eclampsia by a combination of sFlt-1, CT-pro ET1 and blood pressure: exploratory study. ( 28643875 )
2017
12
Severe pre-eclampsia before 26A weeks of gestation: how should we counsel women? ( 28229528 )
2017
13
Re: Lung and cardiac ultrasound for hemodynamic monitoring of patients with severe pre-eclampsia. J. Ambrozic, G. Brzan Simenc, K. Prokselj, N. Tulz, M. Cvijic and M. Lucovnik. Ultrasound Obstet Gynecol 2017; 49: 104-109. ( 28058788 )
2017
14
Lung and cardiac ultrasound for hemodynamic monitoring of patients with severe pre-eclampsia. ( 27736042 )
2017
15
Epidural therapy for the treatment of severe pre-eclampsia in non labouring women. ( 29181841 )
2017
16
Re: Serious maternal complications in relation to severe pre-eclampsia: a retrospective cohort study of the impact of hospital volume; Severe maternal morbidity requires regionalisation of obstetric critical care; Guilt, blame and litigation: can an overenthusiastic 'safety culture' cause harm?: Maternal mortality: the heavy psychological burden on centre obstetricians. ( 28670731 )
2017
17
Evaluation of Placental mir-155-5p and Long Non-coding RNA sONE Expression in Patients with Severe Pre-eclampsia. ( 28868266 )
2017
18
Isolated sixth Cranial Nerve Palsy in a Case Of Severe Pre-Eclampsia Presenting as Postpartum Diplopia. ( 28969214 )
2017
19
Severe pre-eclampsia is associated with alterations in cytotrophoblasts of the smooth chorion. ( 28232601 )
2017
20
Epigallocatechin gallate enhances treatment efficacy of oral nifedipine against pregnancy-induced severe pre-eclampsia: A double-blind, randomized and placebo-controlled clinical study. ( 28726273 )
2017
21
Determinants of magnesium sulphate use in women hospitalized at <29 weeks with severe or non-severe pre-eclampsia. ( 29272274 )
2017
22
Introduction of management protocol for early-onset severe pre-eclampsia. ( 28150368 )
2017
23
Ovarian reserve in women with a previous history of severe pre-eclampsia. ( 27604242 )
2016
24
Serious maternal complications in relation to severe pre-eclampsia: a retrospective cohort study of the impact of hospital volume. ( 27770512 )
2016
25
Maternal cardiac haemodynamics in severe pre-eclampsia complicated by acute pulmonary oedema: A review. ( 27866432 )
2016
26
Risk factors for cardiopulmonary dysfunction in early-onset severe pre-eclampsia. ( 27452610 )
2016
27
Relation between Helicobacter pylori infection and severe pre-eclampsia complicated by intrauterine growth restriction in a rural area in Egypt. ( 27624279 )
2016
28
Antenatal corticosteroid therapy for foetal maturation in women with eclampsia and severe pre-eclampsia in a rural hospital in Western Tanzania. ( 27543098 )
2016
29
Antiphospholipid antibodies and the risk of severe and non-severe pre-eclampsia: the NOHA case-control study. ( 26782635 )
2016
30
Author's reply re: Microcirculation in women with severe pre-eclampsia and HELLP syndrome: a case control study. ( 27531337 )
2016
31
Prospective assessment of neurodevelopment in children following a pregnancy complicated by severe pre-eclampsia. ( 27388354 )
2016
32
Expression of the complement system's activation factors in plasma of patients with early/late-onset severe pre-eclampsia. ( 27461873 )
2016
33
Maternal and neonatal outcomes in women with severe pre-eclampsia undergoing cesarean section: a 10-year retrospective study from a single tertiary care center: anesthetic point of view. ( 26952582 )
2016
34
Soluble vascular cell adhesion molecule-1 and magnesium sulfate with nifedipine treatment in Indonesian women with severe pre-eclampsia. ( 28203390 )
2016
35
Ibuprofen versus acetaminophen as a post-partum analgesic for women with severe pre-eclampsia: randomized clinical study. ( 27384376 )
2016
36
Antiretrovirals causing severe pre-eclampsia. ( 27939465 )
2016
37
Cardiac arrest during emergency cesarean section for severe pre-eclampsia and peripartum cardiomyopathy. ( 26927264 )
2016
38
Re: Microcirculation in women with severe pre-eclampsia and HELLP syndrome: a case control study: Effect of timing of extracorporeal membrane oxygenation during HELLP syndrome. ( 27531338 )
2016
39
Oral nifedipine vs. intravenous labetalol for treatment of pregnancy-induced severe pre-eclampsia. ( 27578562 )
2016
40
Complications and maternal mortality from severe pre-eclampsia during the first 48hours in an intensive care unit in Morocco. ( 25638711 )
2015
41
Case of soluble fms-like tyrosine kinase 1 apheresis in severe pre-eclampsia developed at 15 weeks' gestation. ( 26094569 )
2015
42
Association between decreased plasma levels of soluble human leukocyte antigen-G and severe pre-eclampsia. ( 26352061 )
2015
43
Transthoracic echocardiographic assessment of haemodynamics in severe pre-eclampsia and HIV in South Africa. ( 25891669 )
2015
44
Vascular endothelial growth factor (VEGF)-634G/C polymorphism was associated with severe pre-eclampsia and lower serum VEGF level. ( 26486233 )
2015
45
Characteristics and outcomes of patients with eclampsia and severe pre-eclampsia in a rural hospital in Western Tanzania: a retrospective medical record study. ( 26350344 )
2015
46
Circulating chromosome 19 miRNA cluster microRNAs in pregnant women with severe pre-eclampsia. ( 26224638 )
2015
47
[40-OR]: A causal model of magnesium sulphate use in women hospitalized at <29 weeks with severe or non-severe pre-eclampsia. ( 25787390 )
2015
48
Expression of markers of endoplasmic reticulum stress-induced apoptosis in the placenta of women with early and late onset severe pre-eclampsia. ( 25675914 )
2015
49
Criteria-based audit of quality of care to women with severe pre-eclampsia and eclampsia in a referral hospital in Accra, Ghana. ( 25923663 )
2015
50
Third-trimester uterine artery Doppler measurement and maternal postpartum outcome among patients with severe pre-eclampsia. ( 26117553 )
2015

Variations for Severe Pre-Eclampsia

Expression for Severe Pre-Eclampsia

Search GEO for disease gene expression data for Severe Pre-Eclampsia.

Pathways for Severe Pre-Eclampsia

GO Terms for Severe Pre-Eclampsia

Cellular components related to Severe Pre-Eclampsia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.73 ADIPOQ ALB APLN APOH F5 LEP
2 extracellular region GO:0005576 9.47 ADIPOQ ALB APLN APOH F5 FGR
3 platelet alpha granule lumen GO:0031093 9.33 ALB F5 VEGFA

Biological processes related to Severe Pre-Eclampsia according to GeneCards Suite gene sharing:

(show all 20)
# Name GO ID Score Top Affiliating Genes
1 regulation of signaling receptor activity GO:0010469 9.89 ADIPOQ APLN LEP PGF VEGFA
2 platelet degranulation GO:0002576 9.71 ALB APOH F5 VEGFA
3 response to ethanol GO:0045471 9.67 ADIPOQ LEP RBP4 VCAM1
4 lactation GO:0007595 9.63 APLN SERPINC1 VEGFA
5 macrophage differentiation GO:0030225 9.59 MMP9 VEGFA
6 leukocyte tethering or rolling GO:0050901 9.58 LEP VCAM1
7 energy reserve metabolic process GO:0006112 9.58 LEP LEPR
8 induction of positive chemotaxis GO:0050930 9.57 PGF VEGFA
9 negative regulation of gluconeogenesis GO:0045721 9.56 ADIPOQ LEPR
10 glucose homeostasis GO:0042593 9.56 ADIPOQ LEP LEPR RBP4
11 regulation of blood coagulation GO:0030193 9.55 APOH SERPINC1
12 angiogenesis GO:0001525 9.55 APLN LEP LEPR PGF VEGFA
13 sexual reproduction GO:0019953 9.54 LEP LEPR
14 leptin-mediated signaling pathway GO:0033210 9.52 LEP LEPR
15 regulation of bone remodeling GO:0046850 9.51 LEP LEPR
16 positive regulation of mast cell chemotaxis GO:0060754 9.48 PGF VEGFA
17 negative regulation of vasoconstriction GO:0045906 9.43 APLN LEP
18 bone growth GO:0098868 9.32 LEP LEPR
19 response to nutrient GO:0007584 9.26 ADIPOQ LEP SERPINC1 VCAM1
20 response to hypoxia GO:0001666 9.02 ADIPOQ LEP PGF VCAM1 VEGFA

Molecular functions related to Severe Pre-Eclampsia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 signaling receptor binding GO:0005102 9.65 ADIPOQ APLN FGR HLA-G LEP
2 hormone activity GO:0005179 9.5 ADIPOQ APLN LEP
3 heparin binding GO:0008201 9.46 APOH PGF SERPINC1 VEGFA
4 identical protein binding GO:0042802 9.23 ADIPOQ ALB APOH HLA-G LEPR MMP9
5 vascular endothelial growth factor receptor binding GO:0005172 8.96 PGF VEGFA
6 protein binding GO:0005515 10.24 ADIPOQ ALB APOH F5 FGR HIF1AN

Sources for Severe Pre-Eclampsia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....